Please assess the completion status of the following clinical trial:

Trial Title: A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ages ≥18 years，ECOG ≤ 2，Estimated survival time \> 3 months~* Histologically or Cytologically confirmed metastatic pancreatic adenocarcinoma~* Based on Response Evaluation Criteria In Solid Tumors (RECIST1.1), there should be at least one measurable lesion~* Patients have never received systematical anti-cancer therapy~* Laboratory examination meets the following requirements:White blood cell (WBC) ≥3.0×109/L; absolute neutrophil count (ANC) ≥1.5×109/L; Hemoglobin (HB) ≥90g/L; platelet count(PLT) ≥75×109/L; Total bilirubin (TBIL) ≤1.5× normal upper limit (ULN); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN, if accompanied by liver metastasis, ALT and AST≤5×ULN; Serum creatinine (Cr) ≤1×ULN or creatinine clearance (CCr)≥50ml/min;~* Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) \> 50%~* Patients of childbearing age should take appropriate protective measures before enrollment and during the trial~* Volunteer to join the study, sign the informed consent, have good compliance, and cooperate with follow-up~* Ability to follow the study protocol and follow-up procedures.~Exclusion Criteria:~* Patients have ever received any systematical anti-cancer therapy in the past~* Patients who participated in other clinical trials in the past 4 weeks~* According to the investigator, patients who surgically available or potentially treatable(Patients who voluntarily give up surgical treatment can be enrolled after evaluation by the investigator)~* Patients with moderate ascites requiring drainage~* Patients with CNS metastases and/or carcinomatous meningitis~* Patients with history of other primary malignancies except: 1) complete remission before enrollment for at least 2 years and requiring no additional treatment during the study period; 2) Adequately treated non-melanoma skin cancer or lentiform malignancy with no evidence of disease recurrence; 3) Adequately treated carcinoma in situ with no evidence of disease recurrence;~* Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs~* Patients with bleeding tendency.~* Pregnant or lactating women.~* Drug abuse, clinical or psychological or social factors that impact informed consent or the conduct of the study~* Patients who may be allergic to PD-1 monoclonal antibody, anlotinib, albumin-bound paclitaxel and gemcitabine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Penpulimab+Anlotinib+Nab-paclitaxel+Gemcitabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).